Hikma Pharmaceuticals plc

Hikma Pharmaceuticals USA has announced that it will invest $1bn by 2030 in its US-based manufacturing and R&D capabilities as part of a new investment phase. Titled “America Leans on Hikma: Quali

The US Supreme Court requested the Solicitor General’s input in Hikma ’s case on a skinny-label generic of Amarin ’s Vascepa (icosapent ethyl), adding extra gravity to the issue after a federal appe

The US Supreme Court has requested input from the country’s solicitor general in Hikma’s induced infringement skinny-label generic Vascepa (icosapent ethyl) case, giving extra gravity to the matter fo

Hikma is getting ready to make its first launch into the US biosimilars market after receiving US Food and Drug Administration approval for its Starjemza (ustekinumab-hmny) rival to Stelara. Licensed